Page 6 - Pharma Companies

Ipca Labs Q1 results: Net profit rises 18% to Rs 192 cr, revenue up 32%

The firm's revenue from operations rose to Rs 2,093 crore, a 32 per cent rise from Rs 1,585 crore reported in Q1FY24

Aurobindo Pharma Q1FY25 results: Net profit jumps 61% to Rs 919 cr

Aurobindo Pharma on Saturday said its consolidated net profit increased 61 per cent year on year to Rs 919 crore in the first quarter ended June 2024, aided by strong sales across markets. The Hyderabad-based drug maker had reported a net profit of Rs 571 crore in the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement. "We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments," Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy stated. The profitability was sustained by improved gross margins and operational efficiencies, while ramping up our recently commercialised plants, he added. "We are confident in our ability to achieve our growth targets for FY25," Reddy said.

Indian pharma market registers over 6% growth in July '24: Pharmarack

"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report

Gland Pharma Q1 FY25 results: Net profit falls 26%, revenue rises 16%

The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition

Earnings growth priced-in Divi's Labs stock, niche biz to expand: Analysts

Analysts say pharmaceutical company's stock fully priced in

Govt agencies conducting risk-based inspections of pharma units: Nadda

Over 400 drug manufacturing units, including MSMEs, inspected after high frequency of NQS reports

Akums Drugs and Pharmaceuticals sets IPO price band at Rs 646-679 per share

Contract manufacturer Akums Drugs plans expansion; targets higher margins

Torrent Pharma Q1FY25 results: Net profit up 21%, revenue rises 10%

Revenues in the USA market, however, were down by 12 per cent at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24

Pharma companies on track with QR codes to combat counterfeit drugs

Firms term DCGI move 'positive' as it aims at ensuring patient safety

Dr. Reddy's Laboratories joins race to bring new GERD drug to India

Dr. Reddy's will market Vonoprazan tablets under its own brand Vono, and it will be available in two strengths, 10 mg and 20 mg

Cipla receives additional Rs 773.44 crore tax demand from income tax office

Cipla's share price declined by 0.56 per cent, ending the day's trade at Rs 1,507.50 apiece on the BSE

Centre, states must collaborate for global investment in India: Mukesh Aghi

Mukesh Aghi talks about the recent Lok Sabha elections, expectations from the coming Budget, changes in India's regulatory environment.

Glenmark Pharmaceuticals to sell 7.84% stake in Glenmark Life Sciences

The specific price and date of the offer for sale will likely be announced in the future

AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai

This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai

New product launches may continue to fuel GSK Pharma's robust growth

GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding

How Alkem's 83-year-old founder is remaking India's 4th-largest pharma firm

Hailing from Okari, a remote village in Jehanabad district of Bihar, Singh and his brother, Samprada, moved to Mumbai in 1973 to start Alkem Laboratories with a seed capital of Rs 5 lakh

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Pharmaceutical companies prepare to comply with ethical marketing code

Companies must commit that they comply with a code against unethical marketing of drugs

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

AstraZeneca Q4 results: Net profit jumps 128%, revenue rises 34.59%

Strategic collaborations played a crucial role in AstraZeneca's achievements, particularly in enhancing diagnostic capabilities and treatment outcomes